Stella Vnook

Likarda LLC is a cell therapy company that develops enabling technologies to improve the efficacy of cell therapies and provide sustainable reversal for chronic or fatal diseases. The private company's core technology is the core-shell spherification (CSS) technology, which coats cells and biologics with inert hydrogels to ensure they remain at their intended target location within the body and are shielded from potential degradation. Likarda is based in Cambridge, MA. This customizable platform is pivotal in maintaining cell viability and optimizing the delivery of biologics.

Likarda LLC is a cell therapy company that develops enabling technologies to improve the efficacy of cell therapies and provide sustainable reversal for chronic or fatal diseases. The private company's core technology is the core-shell spherification (CSS) technology, which coats cells and biologics with inert hydrogels to ensure they remain at their intended target location within the body and are shielded from potential degradation. Likarda is based in Cambridge, MA. This customizable platform is pivotal in maintaining cell viability and optimizing the delivery of biologics.

Likarda LLC is a cell therapy company that develops enabling technologies to improve the efficacy of cell therapies and provide sustainable reversal for chronic or fatal diseases. The private company's core technology is the core-shell spherification (CSS) technology, which coats cells and biologics with inert hydrogels to ensure they remain at their intended target location within the body and are shielded from potential degradation. Likarda is based in Cambridge, MA. This customizable platform is pivotal in maintaining cell viability and optimizing the delivery of biologics.